Storms W W, Bodman S F, Nathan R A, Busse W W, Bush R K, Falliers C J, O'Hollaren J D, Weg J G
Am J Med. 1986 Nov 14;81(5A):61-6. doi: 10.1016/0002-9343(86)90464-x.
A multi-center, double-blind, 90-day study compared an ipratropium bromide metered-dose inhaler (40 microgram four times a day) with a metaproterenol metered-dose inhaler (1,500 micrograms four times a day) in 164 patients with asthma; of the 144 patients who completed the study, 71 received ipratropium and 73 received metaproterenol. Our results suggest that both drugs were equally effective bronchodilators. Although the shape of the pulmonary function response curves suggested that ipratropium has different bronchodilator kinetics than metaproterenol (in that it has a slower onset of action and a more prolonged duration), comparison of the areas under the curves for the two drugs showed that there was no statistical difference between ipratropium or metaproterenol. The only significant side effects noted with ipratropium were cough and exacerbation of symptoms; no anticholinergic side effects were noted.
一项多中心、双盲、为期90天的研究，将异丙托溴铵定量吸入器（每日4次，每次40微克）与间羟异丙肾上腺素定量吸入器（每日4次，每次1500微克）用于164例哮喘患者进行比较；在完成研究的144例患者中，71例接受异丙托溴铵治疗，73例接受间羟异丙肾上腺素治疗。我们的结果表明，两种药物作为支气管扩张剂的效果相当。虽然肺功能反应曲线的形态提示异丙托溴铵与间羟异丙肾上腺素的支气管扩张动力学不同（即起效较慢且作用持续时间更长），但两种药物曲线下面积的比较显示，异丙托溴铵与间羟异丙肾上腺素之间无统计学差异。异丙托溴铵唯一显著的副作用是咳嗽和症状加重；未观察到抗胆碱能副作用。
